Connect with us

Artificial Intelligence

Todos Medical Enters Into $50M Contract to Supply Tollovid™ and CBD Products to Retail Distributor Company Nerd Hemp



  • 5500 Automated Retail Machines to be Rolled out in Q4/22 and Q1/23
  • $11.5M in Q4/22 Revenue Expected From This Agreement

NEW YORK, NY and TEL AVIV, ISRAEL, Sept. 22, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that it has entered into a distributor agreement to supply its proprietary 3CL protease inhibitor immune support dietary supplement Tollovid™ and botanical ‘0% THC’ CBD products in pill, tincture, gummy, candy and cream finished products to Nerd Hemp, Inc., an automated retail (AI Retail) machine company focused on the distribution of CBD products. AI Retail machines are similar to vending machines, however they use artificial intelligence to monitor product supply to optimize the re-ordering and stocking process. The new Tollovid and CBD products for the AI Retail machines will be manufactured in different adult and pediatric formulations in the Todos’ newly leased Cleburn, Texas-based facility. Nerd Hemp has already been contracted to install 5500 AI Retail machines across the United States in retail outlets including airports, shopping centers, universities, sporting venues, fitness centers, bars, and grocery outlets. These AI Retail machines are located in high traffic and secure locations very similar to the Redbox model. The first deliveries are expected to take place in October in grocery outlets like Lowes Markets, a privately held grocer with over 140 locations in the southwestern United States. Todos anticipates $11.5 million in revenue in the fourth quarter of 2022 from this contract as Nerd Hemp commences its nationwide rollout.

“Being able to gain access to a game-changing supplement such as Tollovid that is ideal for travel, athletic and leisure marketplace was something unique that no other supplier than Todos could deliver,” said RJ Grady, President & CEO of Nerd Hemp. “As we roll out these AI Retail machines into high-trafficked and secure retail locations that have a proven demand for CBD and personal health products, we are excited to be able to introduce Tollovid to the marketplace in lower priced formats that lower the barrier to access for the average consumer in settings where they are looking for extra protection in today’s environment. We think that after a consumer understands our products they will see the value proposition as they expect to regularly meet immune challenges in today’s new normal.”

“We are excited to be able to supply Nerd Hemp with Tollovid and CBD products that will be accessible in secure retail locations nationwide, thereby expanding our Tollovid distribution channels beyond online and expanding our product offering substantially,” said Gerald Commissiong, President & CEO of Todos Medical. “The world has changed in substantial ways over the last 2 years, with a strong desire for more automated checkout options to reduce overall exposure risk. We believe this supply agreement represents a tremendous opportunity to bring high quality botanically-derived products to market and we are excited to be able to do this at scale. We think this offline awareness will translate into online sales as our product gains more exposure to the public.”

According to Granview Research, The global retail vending machine market size was valued at USD 51.91 billion in 2021 and is expected to register a compound annual growth rate (CAGR) of 10.7% from 2022 to 2030.

To learn more about the 3CL protease in SARS-CoV-2 replication, please visit

To purchase Tollovid please visit Amazon or

About Nerd Hemp

Nerd Hemp was founded in 2019 with a focus on launching CBD products to the marketplace through automated retail (AI Retail) machines. After choosing to delay the planned 2020 launch of the brand nationwide, the management team further refined and developed their AI Retail machine distribution relationships in preparation to initiate the delayed launch in the fourth quarter of 2022 and is now emerging from stealth mode. Nerd Hemp intends to launch its CBD AI Retail machines in retail locations nationwide through its strategic distribution channels.

About Tollovid™ and Tollovid Daily™

Tollovid and Tollovid Daily are oral dietary supplement products made from natural ingredients that help support and maintain healthy immune function and also have potent 3CL protease inhibition properties based upon in vitro functional assays that show strong inhibition of 3CL protease activity. Tollovid and Tollovid Daily bind to the active site of the 3CL protease. Tollovid has a 5-day dosing regimen, with 4 doses of 3 pills taken each day that provides maximum immune support. Tollovid Daily is a daily immune support product with a dosing regimen of twice daily. Preliminary data from an ongoing IRB-waived study of customers who used the products to assist with their COVID and Long COVID were recently announced.

To purchase Tollovid please visit Amazon or

About Tollovir™

Tollovir is an oral 3CL protease inhibitor and anti-cytokine therapeutic candidate targeting the Nidovirus group of viruses that includes coronaviruses such as SARS-CoV-2, COVID-19, SARS-CoV-1, MERS and 229E. Tollovir is made from all natural ingredients that are qualified to ensure strong inhibition of the 3CL protease in vitro, as well as strong anti-cytokine activity. Tollovir has successfully completed a Phase 2 clinical trial in Israel for the treatment of patients hospitalized with COVID-19. Tollovir will be developed for the treatment of hospitalized COVID-19 (severe and critical), moderate COVID-19, Long COVID and, potentially, pediatric COVID-19.

About Todos Medical Ltd.

Founded in Rehovot, Israel with offices in New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers. The Company’s state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that examines cancer’s influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos’ two internally developed cancer-screening tests, TMB-1 and TMB-2 have received a CE mark in Europe. Todos recently acquired U.S.-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab currently performing PCR COVID testing, Long COVID Panel analyses, and Provista’s proprietary commercial-stage Videssa® breast cancer blood test. More information on Provista is available at

Todos is also developing blood tests for the early detection of neurodegenerative disorders, such as Alzheimer’s disease. The Lymphocyte Proliferation Test (LymPro Test™) is a diagnostic blood test that determines the ability of peripheral blood lymphocytes (PBLs) and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle. It is believed that certain diseases, most notably Alzheimer’s disease, are the result of compromised cellular machinery that leads to aberrant cell cycle re-entry by neurons, which then leads to apoptosis. LymPro is unique in the use of peripheral blood lymphocytes as a surrogate for neuronal cell function, suggesting a common relationship between PBLs and neurons in the brain.

Todos formed the Israeli-based majority-owned joint venture 3CL Pharma, Ltd with NLC Pharma in March of 2022 to consolidate all of the intellectual property surrounding 3CL protease–based diagnostic testing and development of 3CL protease botanical and pharmaceutical inhibitors that target a fundamental reproductive mechanism of coronaviruses. 3CL Pharma, through Todos’ brand, has commercialized the 3CL protease inhibitor immune support dietary supplement Tollovidin the United States, is developing the dual mechanism 3CL protease inhibitor and anti-cytokine therapeutic drug candidate Tollovir, while also developing the 3CL protease diagnostic TolloTest™.

To purchase Tollovid please visit Amazon or For more information, please visit

Forward-looking Statements

Certain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected clinical development programs and clinical trials. These forward-looking statements are based only on current expectations of management, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for product candidates; competition from other biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from the competition; and laboratory results that do not translate to equally good results in real settings, all of which could cause the actual results or performance to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Todos Medical does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Todos Medical, please refer to its reports filed from time to time with the U.S. Securities and Exchange Commission.

Todos Corporate Contact:

Daniel Hirsch CFO
Todos Medical
917-983-4229 x 104
[email protected]

Todos Press Contact:

Giancarlo Greager
[email protected]

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

Censys Introduces the Ground Truth for Internet Intelligence – The Censys Internet Map




Powering Censys’ Internet Intelligence Platform, the Internet Map provides critical insights to identify, understand and mitigate threats
ANN ARBOR, Mich., Sept. 26, 2023 /PRNewswire/ — Today, Censys, the leading Internet Intelligence Platform for threat hunting and exposure management, announced the Censys Internet Map. As the data foundation that powers the Censys Internet Intelligence Platform, the Censys Internet Map provides users with the most comprehensive, up-to-date collection of global internet infrastructure to empower security and intelligence teams.

In today’s threat landscape, enterprises cannot rely on “good enough” data to defend their organization. Security teams require comprehensive and accurate data to serve as the center for their security solutions – external attack surface management, vulnerability management, zero-trust, and threat detection, investigation, and response – all rely on exposure management data to protect organizations.
The Censys Internet Map offers the fastest discovery and best coverage of internet hosts and services. Through comprehensive scans of the top 100+ ports and proprietary ML-based discovery of services across 65k ports, it reduces false positives by 70%, improving security teams’ ability to successfully map and defend. With the most complete and up-to-date index of hosts and services on the internet, the Censys Internet Map provides users with the three C’s: Coverage, Context and Connections, which are imperative to an organization’s security posture.
“The organizations we work with face growing challenges that make security insights and threat intelligence critically important to delivering on their mission,” commented Mike Riordan, CEO of RavenTek. “Through the powerful capabilities of Censys solutions powered by their Internet Map, our clients are better able to stay ahead of emerging risks, proactively defend their organization, and quickly make data-informed decisions.”
With the widest depth of internet scanning coverage available, the Censys Internet Map scans 45x more services than competitors. This coverage is enriched with detailed context to identify host types, understand how assets are connected and configured, empowering security teams and threat hunters to identify patterns and trends.
“Censys is the only vendor providing this level of detailed visibility and running daily scans to help organizations eliminate false positives and stale data,” said Zakir Durumeric, Co-Founder and Chief Scientist at Censys. “Our intelligence provides threat analysts and security teams with more details to conduct investigations, understand, and block threats – ultimately reducing the risk and impact of a breach. We’re proud that our industry-leading data provides the most complete and up-to-date index of the internet, and are excited to expand this offering for even more users this year.”
To learn more about the Censys Internet Map and its approach to intelligence data and visibility, visit:
About CensysCensys, Inc.™ is the leading Internet Intelligence Platform for Threat Hunting and Exposure Management. Founded in 2017 in Ann Arbor, Michigan, Censys gives organizations the world’s most comprehensive real-time view of global networks and devices. Customers like Google, Cisco, Microsoft, Samsung, Swiss Armed Forces, the U.S. Department of Homeland Security, Cybersecurity & Infrastructure Security Agency, and over 51% of the Fortune 500 rely on the company’s Exposure Management solution for a real-time, contextualized view into their internet and cloud assets. At Censys, you can be yourself. We like it that way. Diversity fuels our mission, and we are committed to inclusion across race, gender, age and identity. To learn more, visit and follow Censys on Twitter.
Logo –

View original content:—the-censys-internet-map-301938734.html

Continue Reading

Artificial Intelligence

Onfido Featured as a Market Leader in Liminal’s Link Index Report for Account Opening in Financial Services




SAN FRANCISCO, Sept. 26, 2023 /PRNewswire/ — Onfido, the global automated identity verification provider, has been recognized as a market leader in Liminal’s highly anticipated Link™Index Report for Account Opening in Financial Services.

The Link Index analyzed over 150 companies claiming to solve Account Opening (AO) in Financial Services and found that only 32 total vendors (21% of the market) have the necessary product capabilities to satisfy buyer demands.  Of these 32 companies, Liminal positioned Onfido as a leading vendor alongside partners Experian and TransUnion (p.11), acknowledged for delivering comprehensive solutions in compliance and fraud prevention for account opening. The report also highlighted that 20% of buyers are actively looking to switch to a better AO vendor.
Download the full report and sign up for the webinar with Liminal examining the latest developments in account openings for financial services.
Fraud prevention and compliance are top of mind for buyers when weighing new solutions. By the end of 2023, it is estimated that $2.2B will be lost to AO fraud from synthetic identities, and with increasing regulation, AML fines are only set to increase from their high of $5B issued last year.*
Onfido was acknowledged as a leader on Liminal’s matrix, scored by Market Presence and Product Execution. Onfido achieved a positive global market presence score of 4.3/5 and a product execution score of 72%, closest to TransUnion, an Onfido partner. Onfido was also noted as a leader in the AO space by 44.9% of respondents and was a recognized brand by over half of buyers, solidifying Onfido as a top company in both these categories. And thanks to its dedicated customer success team, Onfido’s customer satisfaction score was 60.4%, making it a top ten vendor in this category.
“The financial services sector is undergoing a transformative shift in account opening practices, necessitating robust security measures that seamlessly integrate with user experience while adhering to rigorous regulatory requirements,” said Travis Jarae, founder and CEO at Liminal. “Onfido’s Real Identity Platform addresses these challenges, ensuring a streamlined “Know Your Customer” (KYC) and Anti-Money Laundering (AML) compliance process during customer onboarding, while ensuring best-in-class fraud prevention.”
The Onfido Real Identity Platform is designed to secure trust between organizations and their customers throughout the customer lifecycle journey. It automatically verifies a customer’s identity using a smart combination of award-winning document and biometric verification, trusted data sources, and passive fraud signals. Hailed by companies like Adyen, EE (BT), Bunq, DocuSign, Revolut and Remitly, Onfido helps global companies reduce friction and accelerate onboarding for customers with purpose-built features and its Smart Capture SDK, while providing companies the flexibility and freedom to scale with Onfido Studio, the no-code mission control for identity verification.
“Our recognition in Liminal’s Link Index Report underscores Onfido’s commitment to transforming the financial services landscape,” said Mike Tuchen, CEO of Onfido. “Our identity platform empowers financial institutions to more easily navigate complex regulations on a global and regional level while stopping fraudsters and ensuring the best possible user experience.”
This news comes on the heels of other market recognition from Frost & Sullivan, awarding Onfido 2023 Fraud Detection and Prevention Company of the Year,  picking up 7 leader badges in G2’s 2023 Fall Reports, as well as a Strong Performer in Forrester’s Q4 2022 Wave for Identity Verification Solutions.
About Onfido Onfido makes digital identity simple. The company makes it easy for people to access services by digitally verifying them using its Real Identity Platform. The platform allows businesses to tailor verification methods to individual user and market needs in a no-code, orchestration layer – combining the right mix of document and biometric verifications, trusted data sources, and passive fraud signals to meet their risk, friction and regulatory requirements. Partnering with over 1,100 businesses globally, Onfido helps millions of people access services every day – from billion-dollar institutions to hyper growth
About LiminalLiminal is a market intelligence and strategic advisory firm serving digital identity, fintech, cybersecurity solution providers, and the private equity and venture capital community. Since 2016, Liminal has provided strategy and analytical services that support executive decision-making at all product or business lifecycle stages. We advise some of the world’s most prominent and innovative business leaders, investors, and government officials on building, buying, and investing in the next generation of digital identity solutions and technologies. Learn more at and follow news and updates from Liminal on LinkedIn or subscribe to their weekly newsletter.
*Financial Times, “Global anti-money laundering fines surge 50%”
Media contact: [email protected]
Logo –

View original content:

Continue Reading

Artificial Intelligence

Infosys collaborates with Microsoft to accelerate and democratize industry-wide adoption of generative AI




Both companies will help enterprises take an AI-first approach to scale next-generation AI solutions to improve operational efficiencies, drive revenue growth, and enable business transformation
BENGALURU, India, Sept. 26, 2023 /PRNewswire/ — Infosys (NSE: INFY), (BSE: INFY), (NYSE: INFY), a global leader in next-generation digital services and consulting, today announced that it is collaborating with Microsoft to jointly develop industry leading solutions that leverage Infosys Topaz, Azure OpenAI Service and Azure Cognitive Services. Both organizations are bringing together their respective artificial intelligence (AI) capabilities to enhance enterprise functions with AI-enabled solutions across multiple industries. The integrated solutions will accelerate rapid democratization of data and intelligence that will help businesses increase productivity and drive new revenue growth.

Generative AI has opened new avenues of AI applications and key enterprise functions across industries, and Infosys is providing services, frameworks, solutions, and platforms in multiple application areas, such as semantic search, document summarization, contact center transformation, AI-augmented software development lifecycle (SDLC) and marketing content creation. For example, Infosys helped a leading financial services company implement an AI-based solution to generate document summaries and provide a semantic search capability using generative AI. This resulted in automated organization of documents, which significantly reduced efforts and improved productivity of their financial advisors.
Through the collaboration with Microsoft, Infosys Topaz is using Azure OpenAI Service and Azure Cognitive Services to augment its capabilities, in order to help enterprise customers transition from digital to AI solutions. The integrated solutions will boost customers’ operational efficiency, decrease turn-around-time, future-proof investments, and open new business models.
Balakrishna D. R. (Bali), Executive Vice President and Global Head – AI and Automation, Application Development & Maintenance, Infosys, said, “Infosys Topaz is empowering businesses with improved operational efficiencies and reduced time-to-market for launching new products and services. It converges the power of Infosys Cobalt and data analytics to AI-power business and deliver cognitive solutions and intuitive experiences that revitalize growth. Through our strategic collaboration with Microsoft, we will continue to lead the generative AI revolution, helping businesses amplify human potential and navigate their next towards becoming AI-first enterprises.”
Nicole Dezen, Chief Partner Officer, Microsoft Corp, said, “We’re pleased to expand our collaboration with Infosys to deliver innovative solutions, utilizing Azure OpenAI Service and Azure Cognitive Services, that will help customers develop new business models, and realize new revenue streams. By harnessing the power of generative AI, Infosys will help customers accelerate growth and innovation.”
About Infosys
Infosys is a global leader in next-generation digital services and consulting. Over 300,000 of our people work to amplify human potential and create the next opportunity for people, businesses and communities. We enable clients in more than 56 countries to navigate their digital transformation. With over four decades of experience in managing the systems and workings of global enterprises, we expertly steer clients, as they navigate their digital transformation powered by cloud and AI. We enable them with an AI-first core, empower the business with agile digital at scale and drive continuous improvement with always-on learning through the transfer of digital skills, expertise, and ideas from our innovation ecosystem. We are deeply committed to being a well-governed, environmentally sustainable organization where diverse talent thrives in an inclusive workplace.
Visit to see how Infosys (NSE, BSE, NYSE: INFY) can help your enterprise navigate your next.
Safe Harbor
Certain statements in this release concerning our future growth prospects, or our future financial or operating performance are forward-looking statements intended to qualify for the ‘safe harbor’ under the Private Securities Litigation Reform Act of 1995, which involve a number of risks and uncertainties that could cause actual results or outcomes to differ materially from those in such forward-looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding the execution of our business strategy, our ability to attract and retain personnel, our transition to hybrid work model, economic uncertainties, technological innovations such as Generative AI, the complex and evolving regulatory landscape including immigration regulation changes, our ESG vision, our capital allocation policy and expectations concerning our market position, future operations, margins, profitability, liquidity, capital resources, and our corporate actions including acquisitions. Important factors that may cause actual results or outcomes to differ from those implied by the forward-looking statements are discussed in more detail in our US Securities and Exchange Commission filings including our Annual Report on Form 20-F for the fiscal year ended March 31, 2023. These filings are available at Infosys may, from time to time, make additional written and oral forward-looking statements, including statements contained in the Company’s filings with the Securities and Exchange Commission and our reports to shareholders. The Company does not undertake to update any forward-looking statements that may be made from time to time by or on behalf of the Company unless it is required by law.

View original content:

Continue Reading

Latest News